1 / 7

Ilaris (ACZ885, canakinumab )

Ilaris (ACZ885, canakinumab ). 2013 PR & Communications Plan 20 September 2012. This document represents proposals for discussion by Management.

sarah-mcknight
Télécharger la présentation

Ilaris (ACZ885, canakinumab )

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Ilaris (ACZ885, canakinumab) 2013 PR & Communications Plan 20 September 2012 This document represents proposals for discussion by Management. Strategies / Concepts / Projects described herein may need significant modifications before implementation, and no project should be considered final until it has been fully approved by the appropriate Novartis review process. Novartis will only implement programs that are fully consistent with all applicable laws and regulations as well as Novartis companies’ policies. The sales estimates described in this document are based on the impact of Marketing Activities.

  2. Who is with you here today Rote Frazao Marques Global Head, Franchise Communications IHC Sarah Cornhill Account strategic lead Director, B-M (NY) Deborah Burrage Day-to-day client lead Manager, B-M (London) Helene Ellison Senior strategistGlobal Chair, B-M (NY) | 2013 PR & Communications Plan

  3. Today’s agenda • 2013 PR strategy built on five Ilaris PR strategic imperatives • Our strategic and creative vision to drive the Ilaris value story • Our vision for the future • Critical steps to take in 2013 • Ilaris programming • Orchestration for success | 2013 PR & Communications Plan

  4. Ilaris to 2014 and beyond: ensuring success through multiple launches (SJIA+GA) ENSURE SUCCESSFUL LAUNCHES & UPTAKE; (AI) UNDERSTAND MARKET (SJIA+GA) ENSURE CONTINUED GROWTH; (AI) ENSURE SUCCESSFUL LAUNCHES & UPTAKE QUESTIONS ADDRESSED 2012 2013 2014 | 2013 PR & Communications Plan

  5. Our charge… Highlight Ilaris value proposition, emphasizing unmet need and establishing Novartis leadership in drug discovery for an innovative, targeted approach to treating inflammatory conditions | 2013 PR & Communications Plan

  6. Your strategic imperatives adapted for PR SI1 SI2 SI3 SI4 SI5 Emphasize unmet needs of target patient populations to reconfirm Ilaris unique value proposition Ensureunderstandingof IL-1B askeydriverofinflammatoryconditions, linkedtoNovartis laser-focus on science Expand scientific and community understanding of Ilaris efficacy and safety Continue to identify, up-skill and harness Ilaris product and disease champions (internal and external) Ensure market preparedness for upcoming launches SI1 | 2013 PR & Communications Plan

  7. OUR INSIGHTS | 2013 PR & Communications Plan

More Related